Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 31Pancreatic Neoplasms 8Colorectal Neoplasms 7Biliary Tract Neoplasms 5Neoplasm Metastasis 4Breast Neoplasms 3Recurrence 2Gastrointestinal Neoplasms 2Carcinoma, Hepatocellular 2Advanced Gastric Cancer 2Rectal Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Liver Diseases 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Bile Duct Neoplasms 1Advanced Solid Tumors 1Advanced Biliary Tract Cancer 1

Interventions

Gemcitabine 4lenvatinib 3durvalumab 3Cisplatin 3tislelizumab 2sintilimab 2pembrolizumab 2toripalimab 1titanium silicide 1theasinensin A 1surufatinib 1sitravatinib 1regorafenib 1S 1 (combination) 1Nivolumab 1Injections 1Folfox protocol 1Fluorouracil 1Cryosurgery 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Biliary Tract Cancer × titanium silicide × Clear all
NCT04172402 2025-07-22

NGS as the First-line Treatment in Advanced Biliary Tract Cancer

National Health Research Institutes, Taiwan

Phase 2 Completed
48 enrolled
Gastrointestinal

Advanced Biliary Tract Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡